Browsing Tag
Health Canada
19 posts
Can Portela’s once-quarterly dosing unlock the next phase of Zoetis’ feline pain franchise?
Zoetis launches Portela in Canada and Europe, offering cats three months of osteoarthritis pain relief while testing veterinary uptake.
Picard Medical can lift PMI’s quoted price 50-fold, but can it repair the balance sheet?
Picard Medical’s share consolidation could strengthen its quoted price and preserve market access, but investors still need evidence of improved equity, liquidity and commercial scale.
Atrium Therapeutics (Nasdaq: RNA) Q1 results show cash runway and clinical urgency behind precision cardiology bet
Atrium has cash and RNA ambition. The harder test is whether heart-targeted delivery can turn rare cardiomyopathy science into clinical proof.
Can Celltrion’s Eydenzelt disrupt Canada’s aflibercept market after Health Canada approval?
Celltrion secures Health Canada approval for Eydenzelt, its aflibercept biosimilar. Explore how it aims to disrupt Canada’s high-cost eye care drug market.
Can asciminib reshape first-line CML treatment? Inside Scemblix’s rise as a new standard of care in Canada
More than a month after Health Canada’s approval, Scemblix is forcing a rethink of chronic myeloid leukemia therapy—and raising the bar for tolerability and precision.
Quebec lists Takeda’s FRUZAQLA for metastatic colorectal cancer under RAMQ formulary
Quebec approves public reimbursement of Takeda’s FRUZAQLA for metastatic colorectal cancer, expanding treatment access in Canada.
How Canada became the preferred launchpad for ophthalmic biosimilars in 2025
With Yesafili’s approval, Canada is emerging as the global launchpad for ophthalmic biosimilars. Explore what’s driving this strategic shift.
Biocon Biologics gets Health Canada approval for Yesafili aflibercept biosimilar
Biocon Biologics wins Health Canada approval for Yesafili, its 10th biosimilar. Find out how this launch could reshape retinal care access in Canada.
Takeda’s FRUZAQLA gains Health Canada approval, offering hope for metastatic colorectal cancer patients
Takeda Canada Inc. has achieved a significant milestone with the Health Canada approval of FRUZAQLA (fruquintinib), a targeted…
Canada approves GSK’s Arexvy vaccine for RSV protection in adults 50-59 at elevated risk
In a crucial development for public health, Health Canada has extended its approval for GlaxoSmithKline’s Arexvy vaccine to…